This trial is evaluating whether 131 I-omburtamab will improve 1 primary outcome in patients with Desmoplastic Small Round Cell Tumor. Measurement will happen over the course of Up to 2 years after treatment is discontinued.
This trial requires 55 total participants across 3 different treatment groups
This trial involves 3 different treatments. 131 I-omburtamab is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
We found DS-RT, as the most probable underlying pathogen, in 14.1% of our cases. This is significantly higher than the estimated age and sex-adjusted incidence in the US and in the literature. We suggest that the incidence of DS-RT may be significantly underreported.
There are 3 categories of DSRCT, each with a different prognosis. Patients should be informed pretherapeutically about these characteristics. This article provides an account of the diagnostic characteristics, clinical course, prognosis, and biological characteristics of DSRCT. Understanding these factors will help clinicians manage DSSCT patients.
Patients diagnosed with DSRCT or with stage IV disease might benefit from more aggressive management and the inclusion of more cytotoxic drugs or targeted therapies.
The current research demonstrated that desmoplastic small round cell tumor is not a hereditary cancer. Desmoplastic small round cell tumor occurs due to abnormalities in the genes and proteins which control cell growth, division and apoptosis. Most common type of desmoplastic small round cell tumor occurs in young children, but this disease is still a rare disease with sporadic form. This is a group of tumors which affects mainly children under the age of three, and they cause a rapid death. Desmoplastic small round cell tumor is diagnosed after performing an MRI scan and pathologic examination of the tumor which reveals the characteristic round or ovoid shaped cells are seen.
There are clinical features that suggest a diagnosis of DS-SCT. These features include large tumor size, presence of lytic disease, elevated tumor markers, rapid growth, and recurrent disease.
Desmoplastic small round cell tumor can be effectively treated with chemotherapy alone, especially if it is resected at the time of diagnosis. Patients with desmoplastic small round cell tumor should be followed with serial imaging for at least 6 years after chemotherapy has cleared the tumor.
131 i-labeled ombertrafiban and 131 I-labeled bevacizumab have similar tumor uptake with PET/CT. Based on tumor uptake and tumor uptake/tumor mass ratio, 131 i-labeled omburtamab has higher tumor cell uptake. After correcting tumor uptake for tumor mass, 131 i-labeled omburtamab may have higher tumor uptake, which, in turn, may explain part of its better antitumor activity.
Although some of the SPSs have shown a high degree of penetrance, the fact that DS-SPS is a very rare tumor raises questions as to whether it can be considered a single entity.
Data from a recent study suggest that the incidence of DSRCT is extremely low (0.005%) in general and much lower in adults compared with children. Based on these results, we suggested that a child must have at least two tumors other than DSRCT to have a higher likelihood of developing it.
Desmoplastic SMRCC has a similar survival rate as its Ewing's sarcoma counterpart. The survival rate has not changed much over the past 30 years. Survival seems to be lower in patients with metastatic disease.
The majority of patients responded to initial treatment. However, the overall response rate was low, and the median DSS was 6.6% at 5-year DSS. To make the best out of DSS, patients and medical oncologists need to keep each other informed about clinical trials, and patients need to know that the chances of them achieving a favorable outcome are very limited.
An anti-CD20 radioimmunotoxin based on antibody 131I combined with a monoclonal antibody has been demonstrated to induce target cell kill in the test cancer cell line MOP-2. It has been found that the radiation dose required to achieve tumor cell kill is in the 10 Bq range. In the MOP-II cell line, tumour cell death was seen after administration of 100 micrograms of a mAbs/131I (0.1%) dose combination or after administration of 100 micrograms of a low-mass (11 kDa) mAb/131I (3% or 50 kBq) mixture.